Skip to content

Latest disclosed trades

Every stock trade disclosed by members of Congress, the executive branch and company insiders — newest first.

See the trades

Updated Oct 17 · 1 feed behind: Insider filings, 5 days · Every feed →

All 48Congress 0Executive branch 0Insiders 48
AllBuysSells
Filed late
More filters
DemRepInd
HouseSenateExecutive
$15K+$50K+$100K+$250K+$1M+
Clear filters

ELVN · Insiders · 48 trades

Trades
48
Buys 0 · Sells 48
People
8
Stocks
1
Disclosed value
$168M
range midpoints · Congress & executive
Filed late
6
  1. ▼ SELLOrbimed Advisors LLC 10% ownerELVN Enliven Therapeutics, Inc.$66.5Kdisclosed Jun 24 · filed 2 days after the trade
  2. ▼ SELLOrbimed Advisors LLC 10% ownerELVN Enliven Therapeutics, Inc.$2.1Mdisclosed Jun 24 · filed 2 days after the trade
  3. ▼ SELLOrbiMed Genesis GP LLC 10% ownerELVN Enliven Therapeutics, Inc.$2.1Mdisclosed Jun 24 · filed 2 days after the trade
  4. ▼ SELLOrbiMed Capital GP VII LLC 10% ownerELVN Enliven Therapeutics, Inc.$66.5Kdisclosed Jun 24 · filed 2 days after the trade
  5. ▼ SELLOrbiMed Capital GP VII LLC 10% ownerELVN Enliven Therapeutics, Inc.$1.1Mdisclosed Jun 24 · filed 2 days after the trade
  6. ▼ SELLOrbiMed Genesis GP LLC 10% ownerELVN Enliven Therapeutics, Inc.$66.5Kdisclosed Jun 24 · filed 2 days after the trade
  7. ▼ SELLOrbiMed Genesis GP LLC 10% ownerELVN Enliven Therapeutics, Inc.$1.1Mdisclosed Jun 24 · filed 2 days after the trade
  8. ▼ SELLOrbiMed Capital GP VII LLC 10% ownerELVN Enliven Therapeutics, Inc.$35.7Mdisclosed Jun 24 · filed 2 days after the trade
  9. ▼ SELLOrbimed Advisors LLC 10% ownerELVN Enliven Therapeutics, Inc.$35.7Mdisclosed Jun 24 · filed 2 days after the trade
  10. ▼ SELLOrbiMed Capital GP VII LLC 10% ownerELVN Enliven Therapeutics, Inc.$2.1Mdisclosed Jun 24 · filed 2 days after the trade
  11. ▼ SELLOrbiMed Genesis GP LLC 10% ownerELVN Enliven Therapeutics, Inc.$35.7Mdisclosed Jun 24 · filed 2 days after the trade
  12. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$149Kdisclosed Jun 22 · filed 5 days after the trade · late
  13. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$55.4Kdisclosed Jun 22 · filed 5 days after the trade · late
  14. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$59Kdisclosed Jun 22 · filed 5 days after the trade · late
  15. ▼ SELLHelen Louise Collins Chief Medical OfficerELVN Enliven Therapeutics, Inc.$114Kdisclosed Jun 22 · filed 5 days after the trade · late
  16. ▼ SELLHelen Louise Collins Chief Medical OfficerELVN Enliven Therapeutics, Inc.$54.3Kdisclosed Jun 22 · filed 5 days after the trade · late
  17. ▼ SELLHelen Louise Collins Chief Medical OfficerELVN Enliven Therapeutics, Inc.$50.7Kdisclosed Jun 22 · filed 5 days after the trade · late
  18. ▼ SELLOrbiMed Capital GP VII LLC 10% ownerELVN Enliven Therapeutics, Inc.$12.3Mdisclosed Jun 17 · filed 2 days after the trade
  19. ▼ SELLOrbimed Advisors LLC 10% ownerELVN Enliven Therapeutics, Inc.$12.3Mdisclosed Jun 17 · filed 2 days after the trade
  20. ▼ SELLOrbimed Advisors LLC 10% ownerELVN Enliven Therapeutics, Inc.$409Kdisclosed Jun 17 · filed 2 days after the trade
  21. ▼ SELLOrbiMed Capital GP VII LLC 10% ownerELVN Enliven Therapeutics, Inc.$409Kdisclosed Jun 17 · filed 2 days after the trade
  22. ▼ SELLOrbiMed Genesis GP LLC 10% ownerELVN Enliven Therapeutics, Inc.$409Kdisclosed Jun 17 · filed 2 days after the trade
  23. ▼ SELLOrbiMed Genesis GP LLC 10% ownerELVN Enliven Therapeutics, Inc.$12.3Mdisclosed Jun 17 · filed 2 days after the trade